Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) had its price target boosted by Morgan Stanley from $80.00 to $100.00 in a research report released on Wednesday, Marketbeat Ratings reports. Morgan Stanley currently has an equal weight rating on the biotechnology company’s stock.
Several other analysts have also recently commented on the company. StockNews.com cut Sarepta Therapeutics from a buy rating to a hold rating in a report on Saturday, May 21st. Barclays raised their price target on Sarepta Therapeutics from $104.00 to $125.00 in a report on Wednesday. Oppenheimer raised their price target on Sarepta Therapeutics from $125.00 to $150.00 in a report on Wednesday. Needham & Company LLC raised their price target on Sarepta Therapeutics from $150.00 to $162.00 and gave the company a buy rating in a report on Friday, July 29th. Finally, Cantor Fitzgerald dropped their price objective on Sarepta Therapeutics from $140.00 to $128.00 and set an overweight rating for the company in a research note on Friday, June 24th. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of Moderate Buy and a consensus target price of $126.92.
Sarepta Therapeutics Stock Up 4.5 %
Sarepta Therapeutics stock opened at $106.02 on Wednesday. The company has a current ratio of 4.53, a quick ratio of 5.13 and a debt-to-equity ratio of 1.52. The stock has a 50 day moving average of $78.23 and a two-hundred day moving average of $76.58. The stock has a market capitalization of $9.28 billion, a price-to-earnings ratio of -18.06 and a beta of 1.27. Sarepta Therapeutics has a twelve month low of $61.28 and a twelve month high of $107.03.
Hedge Funds Weigh In On Sarepta Therapeutics
Hedge funds have recently bought and sold shares of the stock. Exchange Traded Concepts LLC increased its position in Sarepta Therapeutics by 191.7% during the second quarter. Exchange Traded Concepts LLC now owns 633 shares of the biotechnology company’s stock worth $47,000 after buying an additional 416 shares in the last quarter. UMB Bank N A MO purchased a new position in Sarepta Therapeutics during the fourth quarter worth $69,000. IndexIQ Advisors LLC purchased a new position in Sarepta Therapeutics during the first quarter worth $61,000. KRS Capital Management LLC purchased a new position in Sarepta Therapeutics during the fourth quarter worth $96,000. Finally, Laurel Wealth Planning LLC purchased a new position in Sarepta Therapeutics during the first quarter worth $117,000. Hedge funds and other institutional investors own 81.43% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.
- Get a free copy of the StockNews.com research report on Sarepta Therapeutics (SRPT)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.